Aberrant methylated EDNRB can act as a potential diagnostic biomarker in sporadic colorectal cancer while KISS1 is controversial

Abstract

Cancers are among the most serious threats of human health worldwide. Survival and mortality rates of colorectal cancer (CRC) strongly depend on the early diagnosis. The aberrant methylation pattern of genes as a diagnostic biomarker can serve as a practical option for timely detection and contribute subsequently to the enhancement of survival rate in CRC patients, since methylation changes are not only frequent but also can occur in initial tumorogenesis stages. It has been indicated that EDNRB and KISS1 genes are hypermethylated through progression and development of CRC. In current study, after extraction of genomic DNA from 45 paired tumor and adjacent noncancerous tissue samples and treatment with bisulfite conversion, the methylation status of EDNRB and KISS1 CpG rich regions were assessed quantitatively using MS-HRM assay to determine practicability of these aberrant methylations for diagnosis of sporadic CRC and its discrimination from corresponding normal tissues. The results showed that the methylation distribution differences, comparing tumor tissues with their adjacent non-cancerous tissues, were statistically significant in all selected locations within EDNRB gene promoter (P < 0.001); they had also some correlations with tumor stage and grade. Nonetheless, methylation distribution in KISS1 gene CpG rich region revealed no statistically significant differences between CRC and adjacent noncancerous tissues (P D 0.060). Overall, it can be concluded that aberrant methylated EDNRB can be a promising potential diagnostic biomarker for CRC, while KISS1 is controversial and needs to be more investigated.

Clinical Value and Potential Mechanism of miRNA-33a-5p in Lung Squamous Cell Carcinoma

“…Our result indicated that ETS1 was prominently downregulated in LUSC and closely implicated with prognosis of LUSC patients, which strongly suggests that ETS1 may be a promising biomarker of LUSC and attractive target gene of miRNA-33a-5p in LUSC. Endothelin receptor type B (EDNRB) is usually underexpressed or even silenced by promoter hypermethylation in various human cancers by acting as an oncosuppressor [ 47 – 50 ]. In the field of LC, Wei et al [ 51 ] uncovered that EDNRB acted as a prognostic factor for LUAD patients by regulating the ERK signaling pathway.…”

Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review

“…A panel of methylated biomarkers was also employed-C9orf50 was assessed together with CLIP4 and KCNQ5 [78], with TWIST1 [79] or just with KCNQ5 [80]. Other potential biomarkers and their performance are displayed in Table S4 [81][82][83][84][85][86][87][88][89][90].…”

Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview

“…KISS1R is also a G-protein coupled receptor that is associated with tumor metastasis by ERK inhibition and MMP-9 reduction [ 161 , 162 ]. It has been reported that there was higher frequency of EDNRB hyper methylation in a sample of Iranian colorectal cancer tissues compared with normal margins [ 55 ]. Similarly, the Chinese colorectal cancer tumors had significantly higher frequency of EDNRB promoter hyper methylation compared with normal tissues [ 155 ].…”

“… Amini [ 54 ] EDNRB 2017 Colorectal 45 N/T Tissue Hyper methylation. Mousavi Ardehaie [ 55 ] signaling pathways APC, DDK3, SFRP2, SFRP4, SFRP5, WIF1, WNT5A 2014 Colorectal 125 N/T Tissue Aberrant methylations. Samaei [ 56 ] APC 2009 Esophageal 45 N/T Tissue Hyper methylation.…”